CLINICAL TRIALS AND OBSERVATIONS Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years’ follow-up
نویسندگان
چکیده
1Universitá di Milano, Ca Granda Foundation Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy; 2Centre National de Greffe de Moelle Osseuse, Bab Saadoun, Tunis, Tunisia; 3Istanbul University Medical Faculty, Istanbul, Turkey; 4Suleyman Demirel University Medical Faculty, Isparta, Turkey; 5Ospedale Civico, G Di Cristina e Benfratelli, Palermo, Italy; 6Children’s Hospital of Philadelphia, Philadelphia, PA; 7Hospital de Ninos Ricardo Gutierrez, Buenos Aires, Argentina; 8Hippokration General Hospital of Thessaloniki, Thessaloniki, Greece; 9Hospital d’Enfants, Tunis, Tunisia; 10First Department of Pediatrics, University of Athens, Athens, Greece; 11Cukurova University Medical Faculty, Adana, Turkey; 12I Policlinico II Universitá di Napoli, Naples, Italy; 13Universitá di Torino, Turin, Italy; 14University College London, London, United Kingdom; 15Novartis Pharmaceuticals, East Hanover, NJ; 16Novartis Pharma AG, Basel, Switzerland; and 17Ege University Medical Faculty, Izmir, Turkey
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Effect of transfusional iron intake on response to chelation therapy in -thalassemia major
The success of chelation therapy in controlling iron overload in patients with thalassemia major is highly variable and may partly depend on the rate of transfusional iron loading. Using data from the 1-year phase III study of deferasirox, including volumes of transfused red blood cells and changes in liver iron concentration (LIC) in 541 patients, the effect of iron loading on achieving neutra...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial
1The Catholic University of Korea, Seoul, South Korea; 2Seoul National University College of Medicine, Seoul, South Korea; 3Ruijin Hospital, Shanghai Second Medical University, Shanghai, China; 4Medizinische Hochschule Hannover, Hannover, Germany; 5Taipei City Hospital, Taipei, Taiwan; 6Novartis Pharmaceuticals, East Hanover, NJ; 7Novartis Pharma AG, Basel, Switzerland; and 8University College ...
متن کاملPlenary Paper CLINICAL TRIALS AND OBSERVATIONS A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in b-thalassemia major (CORDELIA)
A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in b-thalassemia major (CORDELIA) Dudley J. Pennell, John B. Porter, Antonio Piga, Yongrong Lai, Amal El-Beshlawy, Khawla M. Belhoul, Mohsen Elalfy, Akif Yesilipek, Yurdanur Kilinç, Tomasz Lawniczek, Dany Habr, Marianne Weisskopf, Yiyun Zhang, and Yesim Aydinok, on behalf of the CORDELIA study invest...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Stroke With Transfusions Changing to Hydroxyurea (SWiTCH)
Stroke is a devastating complication of sickle cell anemia (SCA) with high recurrence if untreated. Chronic transfusions reduce recurrent strokes but have associated morbidities including iron overload. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH) was a multicenter phase 3 randomized trial comparing standard treatment (transfusions/chelation) to alternative treatment (hydroxyurea/p...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia
The aim of this study was to determine the efficacy and safety of treatment of pediatric acute promyelocytic leukemia (APL) with single-agent arsenic trioxide (ATO). A total of 19 children (< 15 years of age) with newly diagnosed APL were treated with single-agent ATO for remission induction and postremission therapy. Seventeen of the children (89.5%) achieved complete hematologic remission, an...
متن کامل